Time to Clinical Benefit of Dapagliflozin and Significance of Prior Heart Failure Hospitalization in Patients With Heart Failure With Reduced Ejection Fraction

IMPORTANCE: Dapagliflozin has been shown to reduce the risk of cardiovascular death or worsening heart failure (HF) in patients with chronic HF and reduced ejection fraction (HFrEF). However, clinical inertia often underlies deferred initiation of effective therapies. OBJECTIVE: To examine timing of...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:JAMA Cardiol
Main Authors: Berg, David D., Jhund, Pardeep S., Docherty, Kieran F., Murphy, Sabina A., Verma, Subodh, Inzucchi, Silvio E., Køber, Lars, Kosiborod, Mikhail N., Langkilde, Anna Maria, Martinez, Felipe A., Bengtsson, Olof, Ponikowski, Piotr, Sjöstrand, Mikaela, Solomon, Scott D., McMurray, John J. V., Sabatine, Marc S.
Formato: Artigo
Idioma:Inglês
Publicado em: American Medical Association 2021
Assuntos:
Original Investigation
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC7890451/
https://ncbi.nlm.nih.gov/pubmed/33595593
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1001/jamacardio.2020.7585
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados